CTRI/2022/07/044179已完成3 期
A Randomized, Double Blind, Active Controlled, Parallel Group, Multicentric, Phase-III clinical trial to compare the Efficacy, Safety and Tolerability of FDC of Dapagliflozin 10 mg plus Linagliptin 5mg tablets versus FDC of Dapagliflozin 10 mg plus Vildagliptin SR 100 mg Tablets in patients with Type 2 Diabetes Mellitus
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 229
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Subjects aged >=18 to <=65 years of age of both gender with diagnosis of Type 2 diabetes mellitus.
- •2. Inadequate glycemic control at screening defined as HbA1c levels of >=8.0% to <= 11.0%.
- •3. Subjects who have received stable dose of metformin IR /ER > 1500 mg/day ( > 1000mg/day for subjects not tolerating) as monotherapy for at least 8 weeks prior to screening
- •4. Subjects with BMI less than or equal to 45.0 kg/m2 at screening
- •5. Female subjects of childbearing potential using adequate contraception
- •6. Willingness to sign written informed consent document
排除标准
- •1.Women of childbearing potential if pregnant (test positive for pregnancy) at screening visit, breast feeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study
- •2.Patients with Fasting Plasma Glucose (FPG) > 270 mg/dL at screening (If FPG is > 270 mg/dL at screening, FPG will be repeated within 1 week. If repeat FPG is > 270 mg/dL, patient will be excluded from the study).
- •3.Patients with Estimated glomerular filtration rate (eGFR) <60mL/min/1.73 m2 [using the Modification of Diet in Renal Disease(MDRD) equation] at screening.
- •4.Patients with clinically significant impaired hepatic function (SGOT &SGPT more than 3X the UNL and/or Total bilirubin more than 2X the UNL) at screening.
- •5.Subjects with History of metabolic acidosis or diabetic ketoacidosis
- •6.Patients with a history of congestive heart failure defined as New York Heart Association (NYHA) class III/IV, unstable or acute congestive heart failure.
- •7.Subjects with symptomatic urinary tract infection or mycotic genital infection at screening or history of a recent symptomatic infection within 4 weeks prior to screening
- •8.Refusal or inability to comply with the requirements of the protocol for any reason, including scheduled clinic visits and laboratory tests.
- •9.Subjects with Intolerance, contraindication or potential allergy/hypersensitivity to any of the ingredients of study medication or any other SGLT2 inhibitors orDPP4 inhibitors
- •10.Any other condition that in opinion of the investigator does not justify patientâ??s participation in study.
- •11.Participation in another clinical trial within past 30 days
研究者
相似试验
已完成
3 期
A Clinical trial to evaluate the pharmacokinetics, safety, efficacy and immunogenicity of Bmab-100 and Avastin in patients with metastatic colorectal cancerCTRI/2014/11/005171Biocon Research Limited146
进行中（未招募）
1 期
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250mcg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma.EUCTR2007-005653-37-CZSkyePharma AG375
进行中（未招募）
1 期
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250mcg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma.Moderate to severe asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-005653-37-PLSkyePharma AG375
已完成
不适用
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250mcg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma.-J45J45PER-011-08Skye Pharma AG,
进行中（未招募）
不适用
A Randomized, Double-blind, Active-controlled, Parallel Group, Stratified, Multi-center, 12-Week Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™ 250/10mcg twice daily) in a Single Inhaler (SkyePharma HFA pMDI) with the Administration of Fluticasone (250mcg twice daily) Alone in SkyePharma HFA pMDI and Flovent® HFA pMDI in Adolescent and Adult Patients with Moderate to Severe Asthma.Moderate to severe asthma.MedDRA version: 9.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2007-005653-37-HUSkyePharma AG375